Vivos, Inc. is a radiation oncology medical device company. The company is headquartered in Richland, Washington. The company went IPO on 2001-08-08. The firm has developed an Yttrium-90-based injectable Precision Radionuclide Therapy medical device to treat tumors in animals (IsoPet) and humans (RadioGel). Using the Company’s proprietary hydrogel technology, PRnT uses highly localized radiation to destroy cancerous tumors by placing a radioactive isotope directly inside the treatment area. The injection delivers therapeutic radiation from within the tumor without the entrance skin dose and associated side effects of treatment that characterize external-beam radiation therapy. This feature allows the safe delivery of higher doses needed for treating non-resectable and radiation-resistant cancers. University veterinary hospitals use the IsoPet Solutions division to demonstrate animal cancers’ safety and therapeutic effectiveness. RadioGel is a hydrogel liquid containing tiny yttrium-90 phosphate microparticles that may be administered directly into a tumor.
Follow-Up Questions
Vivos Inc 'in CEO'su kimdir?
Dr. Michael Korenko 2009 'den beri şirketle birlikte olan Vivos Inc 'in Chief Executive Officer 'ıdır.
RDGL hissesinin fiyat performansı nasıl?
RDGL 'in mevcut fiyatı $0.0788 'dir, son işlem günde 0% decreased etti.
Vivos Inc için ana iş temaları veya sektörler nelerdir?
Vivos Inc Health Care endüstrisine ait ve sektör Health Care 'dir
Vivos Inc 'in piyasa değerlemesi nedir?
Vivos Inc 'in mevcut piyasa değerlemesi $35.7M 'dir
